| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | -100.0% | -100.0% |
| R&D Expense | $13.7M | +4.5% | +237.9% |
| SG&A Expense | $4.0M | +46.7% | +286.5% |
| Operating Income | -$17.7M | -11.7% | -247.7% |
| Net Income | -$16.3M | -13.6% | -290.1% |
| EPS (Basic) | -$0.75 | -13.6% | +28.6% |
| EPS (Diluted) | -$0.75 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $39.3M | +51.1% | — |
| Short-term Investments | $87.1M | -24.8% | — |
| Current Assets | $129.2M | -10.7% | — |
| Total Assets | $133.2M | -9.7% | — |
| Current Liabilities | $10.7M | +4.1% | — |
| Total Liabilities | $10.9M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$37.4M | — | — |
| Capital Expenditures | $95K | — | — |
| Investing Cash Flow | -$74.0M | — | — |
| Financing Cash Flow | $89.0M | — | — |
| Free Cash Flow | -$37.5M | — | — |
| -13.6% |
| +28.6% |
| +2.9% |
| — |
| Stockholders' Equity | $122.4M | -10.6% | +365.0% |